A shortage of organs for transplant has prompted many countries to encourage citizens to register ("opt in") to donate their organs and tissues when they die.
bases, we obtained demographic information and donor registration status. The data were complete with the exception of 4 variables, which each had less than 2% missing data. As of 2008, Ontario's organ and tissue donor registry recorded only yes responses. Citizens at least 16 years of age are able to register online or by mail. Citizens are also prompted to consider registration when renewing their driver license or health card. Those who register can opt to exclude certain organs or tissues from donation (eg, cornea, heart).
A comparison group of Ontario citizens with similar sociodemographic backgrounds as the physicians were selected from the Registered Persons Database, matched (4:1) to each physician on age, sex, income, and residential neighborhood (99% matched). We compared the proportion of physicians registered for organ donation with the general public or matched citizens (χ 2 or McNemar test, respectively; 2-tailed P < .05 interpreted as significant). We used multivariable logbinomial regression to estimate the prevalence ratio and 95% confidence interval of various physician factors associated with donor registration (SAS version 9.3; SAS Institute Inc). 5 The research ethics boards at Sunnybrook Health Sciences Center and Western University approved the study and waived informed consent. Among physicians, factors significantly associated with higher donor registration were younger age, sex (women), living in a rural community, physician specialty (emergency medicine, internal medicine, pediatrics, or psychiatry vs family medicine) and graduating from a Canadian (vs foreign) medical school (Table) .
Figure. Flow Diagram of Participants
Discussion | To our knowledge, this is the first study to document rates of actual organ donor registration among physicians, rather than expressed support for donation. Physicians were more likely to register than the general public. Similar to factors associated with registration in nonphysicians, 6 younger physicians and women were more likely to register. However, half of all physicians were not registered.
One study limitation is that we had data on the majority of, but not all, physicians in the province. We also had no information on the reasons why some physicians were yet to register, which would be useful to address potential barriers. Future research should determine if our findings are generalizable to other countries.
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COMMENT & RESPONSE

Guidelines for Managing High Blood Pressure
To the Editor Some evidence against β-blockers 1 has been published in recent years; however, the exclusion of these drugs as initial treatment of uncomplicated hypertension in the report from the panel members appointed to the Eighth Joint National Committee (JNC 8) 2 is surprising.
First, the evidence against atenolol was presented in only 1 study, the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE), 3 and the quality of this evidence was classified as weak by the panel. Results from LIFE cannot be extrapolated to the general population because the patients included were a high-risk sample with ventricular hypertrophy by electrocardiography and a high prevalence of diabetes mellitus (13%) and cardiovascular disease (25%). Also, the mean age in LIFE was 66.9 years, and it has been shown that β-blockers can be more effective in patients with hypertension who are younger than 60 years. 4 In other studies that analyzed a general population, the performance of β-blockers was similar to that of other drugs or the evidence was not sufficient to draw conclusions. Second, β-blockers differ substantially in their pharmacological properties in ways that may affect their relative efficacy and tolerability. Limitations of atenolol cannot be extrapolated to third-generation β-blockers (eg, carvedilol and nebivolol), which combine antihypertensive and vasodilatory properties. There are currently no mortality and cardiovascular event data on these vasodilating β-blockers as initial therapy for hypertension. 1 Third, in clinical trials, atenolol is typically a once-daily therapy. However, this regimen may not provide a full 24 hours of blood pressure (BP) control. This bias may explain, in part, the reduced benefit in prevention of cardiovascular events attributed to atenolol compared with other antihypertensive agents. 5 If the majority of patients with hypertension will require 2 or more drugs to achieve control of their hypertension, the concern about what antihypertensive drug should be used first becomes less urgent. Instead, we suggest prioritizing the study of combinations of antihypertensive drugs according to age, weight, cost, availability, and other variables.
